TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

Alice L. Hung, Russell Maxwell, Debebe Theodros, Zineb Belcaid, Dimitrios Mathios, Andrew S. Luksik, Eileen Kim, Adela Wu, Yuanxuan Xia, Tomas Garzon-Muvdi, Christopher Jackson, Xiaobu Ye, Betty Tyler, Mark Selby, Alan Korman, Bryan Barnhart, Su Myeong Park, Je In Youn, Tamrin Chowdhury, Chul Kee ParkHenry Brem, Drew M. Pardoll, Michael Lim

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity. In this study, we sought to determine the effect of anti-PD-1 and anti-TIGIT combination therapy on survival in a murine glioblastoma (GBM) model, and to elucidate the underlying immune mechanisms. Using mice with intracranial GL261-luc+ tumors, we found that TIGIT expression was upregulated on CD8+ and regulatory T cells (Tregs) in the brain compared to draining cervical lymph nodes (CLN) and spleen. We then demonstrated that treatment using anti-PD-1 and anti-TIGIT dual therapy significantly improved survival compared to control and monotherapy groups. The therapeutic effect was correlated with both increased effector T cell function and downregulation of suppressive Tregs and tumor-infiltrating dendritic cells (TIDCs). Clinically, TIGIT expression on tumor-infiltrating lymphocytes was shown to be elevated in patient GBM samples, suggesting that the TIGIT pathway may be a valuable therapeutic target. Expression of the TIGIT ligand, PVR, further portended a poor survival outcome in patients with low-grade glioma. We conclude that anti-TIGIT is an effective treatment strategy against murine GBM when used in combination with anti-PD-1, improving overall survival via modifications of both the T cell and myeloid compartments. Given evidence of PVR expression on human GBM cells, TIGIT presents as a promising immune therapeutic target in the management of these patients.

Original languageEnglish (US)
Article numbere1466769
JournalOncoImmunology
Volume7
Issue number8
DOIs
StatePublished - Aug 3 2018
Externally publishedYes

Fingerprint

Glioblastoma
Immunity
Survival
Therapeutics
T-Lymphocytes
Tumor-Infiltrating Lymphocytes
Neoplasms
Therapeutic Uses
Regulatory T-Lymphocytes
Glioma
Dendritic Cells
Down-Regulation
Spleen
Lymph Nodes
Ligands
Control Groups
Brain

Keywords

  • CD155
  • checkpoint inhibitor
  • dendritic cell
  • GBM
  • glioma
  • immunotherapy
  • PD-1
  • PVR
  • TIGIT

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Hung, A. L., Maxwell, R., Theodros, D., Belcaid, Z., Mathios, D., Luksik, A. S., ... Lim, M. (2018). TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology, 7(8), [e1466769]. https://doi.org/10.1080/2162402X.2018.1466769

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. / Hung, Alice L.; Maxwell, Russell; Theodros, Debebe; Belcaid, Zineb; Mathios, Dimitrios; Luksik, Andrew S.; Kim, Eileen; Wu, Adela; Xia, Yuanxuan; Garzon-Muvdi, Tomas; Jackson, Christopher; Ye, Xiaobu; Tyler, Betty; Selby, Mark; Korman, Alan; Barnhart, Bryan; Park, Su Myeong; Youn, Je In; Chowdhury, Tamrin; Park, Chul Kee; Brem, Henry; Pardoll, Drew M.; Lim, Michael.

In: OncoImmunology, Vol. 7, No. 8, e1466769, 03.08.2018.

Research output: Contribution to journalArticle

Hung, AL, Maxwell, R, Theodros, D, Belcaid, Z, Mathios, D, Luksik, AS, Kim, E, Wu, A, Xia, Y, Garzon-Muvdi, T, Jackson, C, Ye, X, Tyler, B, Selby, M, Korman, A, Barnhart, B, Park, SM, Youn, JI, Chowdhury, T, Park, CK, Brem, H, Pardoll, DM & Lim, M 2018, 'TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM', OncoImmunology, vol. 7, no. 8, e1466769. https://doi.org/10.1080/2162402X.2018.1466769
Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology. 2018 Aug 3;7(8). e1466769. https://doi.org/10.1080/2162402X.2018.1466769
Hung, Alice L. ; Maxwell, Russell ; Theodros, Debebe ; Belcaid, Zineb ; Mathios, Dimitrios ; Luksik, Andrew S. ; Kim, Eileen ; Wu, Adela ; Xia, Yuanxuan ; Garzon-Muvdi, Tomas ; Jackson, Christopher ; Ye, Xiaobu ; Tyler, Betty ; Selby, Mark ; Korman, Alan ; Barnhart, Bryan ; Park, Su Myeong ; Youn, Je In ; Chowdhury, Tamrin ; Park, Chul Kee ; Brem, Henry ; Pardoll, Drew M. ; Lim, Michael. / TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. In: OncoImmunology. 2018 ; Vol. 7, No. 8.
@article{f0b3dbb478044389ad892480a1e002af,
title = "TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM",
abstract = "The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity. In this study, we sought to determine the effect of anti-PD-1 and anti-TIGIT combination therapy on survival in a murine glioblastoma (GBM) model, and to elucidate the underlying immune mechanisms. Using mice with intracranial GL261-luc+ tumors, we found that TIGIT expression was upregulated on CD8+ and regulatory T cells (Tregs) in the brain compared to draining cervical lymph nodes (CLN) and spleen. We then demonstrated that treatment using anti-PD-1 and anti-TIGIT dual therapy significantly improved survival compared to control and monotherapy groups. The therapeutic effect was correlated with both increased effector T cell function and downregulation of suppressive Tregs and tumor-infiltrating dendritic cells (TIDCs). Clinically, TIGIT expression on tumor-infiltrating lymphocytes was shown to be elevated in patient GBM samples, suggesting that the TIGIT pathway may be a valuable therapeutic target. Expression of the TIGIT ligand, PVR, further portended a poor survival outcome in patients with low-grade glioma. We conclude that anti-TIGIT is an effective treatment strategy against murine GBM when used in combination with anti-PD-1, improving overall survival via modifications of both the T cell and myeloid compartments. Given evidence of PVR expression on human GBM cells, TIGIT presents as a promising immune therapeutic target in the management of these patients.",
keywords = "CD155, checkpoint inhibitor, dendritic cell, GBM, glioma, immunotherapy, PD-1, PVR, TIGIT",
author = "Hung, {Alice L.} and Russell Maxwell and Debebe Theodros and Zineb Belcaid and Dimitrios Mathios and Luksik, {Andrew S.} and Eileen Kim and Adela Wu and Yuanxuan Xia and Tomas Garzon-Muvdi and Christopher Jackson and Xiaobu Ye and Betty Tyler and Mark Selby and Alan Korman and Bryan Barnhart and Park, {Su Myeong} and Youn, {Je In} and Tamrin Chowdhury and Park, {Chul Kee} and Henry Brem and Pardoll, {Drew M.} and Michael Lim",
year = "2018",
month = "8",
day = "3",
doi = "10.1080/2162402X.2018.1466769",
language = "English (US)",
volume = "7",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

AU - Hung, Alice L.

AU - Maxwell, Russell

AU - Theodros, Debebe

AU - Belcaid, Zineb

AU - Mathios, Dimitrios

AU - Luksik, Andrew S.

AU - Kim, Eileen

AU - Wu, Adela

AU - Xia, Yuanxuan

AU - Garzon-Muvdi, Tomas

AU - Jackson, Christopher

AU - Ye, Xiaobu

AU - Tyler, Betty

AU - Selby, Mark

AU - Korman, Alan

AU - Barnhart, Bryan

AU - Park, Su Myeong

AU - Youn, Je In

AU - Chowdhury, Tamrin

AU - Park, Chul Kee

AU - Brem, Henry

AU - Pardoll, Drew M.

AU - Lim, Michael

PY - 2018/8/3

Y1 - 2018/8/3

N2 - The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity. In this study, we sought to determine the effect of anti-PD-1 and anti-TIGIT combination therapy on survival in a murine glioblastoma (GBM) model, and to elucidate the underlying immune mechanisms. Using mice with intracranial GL261-luc+ tumors, we found that TIGIT expression was upregulated on CD8+ and regulatory T cells (Tregs) in the brain compared to draining cervical lymph nodes (CLN) and spleen. We then demonstrated that treatment using anti-PD-1 and anti-TIGIT dual therapy significantly improved survival compared to control and monotherapy groups. The therapeutic effect was correlated with both increased effector T cell function and downregulation of suppressive Tregs and tumor-infiltrating dendritic cells (TIDCs). Clinically, TIGIT expression on tumor-infiltrating lymphocytes was shown to be elevated in patient GBM samples, suggesting that the TIGIT pathway may be a valuable therapeutic target. Expression of the TIGIT ligand, PVR, further portended a poor survival outcome in patients with low-grade glioma. We conclude that anti-TIGIT is an effective treatment strategy against murine GBM when used in combination with anti-PD-1, improving overall survival via modifications of both the T cell and myeloid compartments. Given evidence of PVR expression on human GBM cells, TIGIT presents as a promising immune therapeutic target in the management of these patients.

AB - The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity. In this study, we sought to determine the effect of anti-PD-1 and anti-TIGIT combination therapy on survival in a murine glioblastoma (GBM) model, and to elucidate the underlying immune mechanisms. Using mice with intracranial GL261-luc+ tumors, we found that TIGIT expression was upregulated on CD8+ and regulatory T cells (Tregs) in the brain compared to draining cervical lymph nodes (CLN) and spleen. We then demonstrated that treatment using anti-PD-1 and anti-TIGIT dual therapy significantly improved survival compared to control and monotherapy groups. The therapeutic effect was correlated with both increased effector T cell function and downregulation of suppressive Tregs and tumor-infiltrating dendritic cells (TIDCs). Clinically, TIGIT expression on tumor-infiltrating lymphocytes was shown to be elevated in patient GBM samples, suggesting that the TIGIT pathway may be a valuable therapeutic target. Expression of the TIGIT ligand, PVR, further portended a poor survival outcome in patients with low-grade glioma. We conclude that anti-TIGIT is an effective treatment strategy against murine GBM when used in combination with anti-PD-1, improving overall survival via modifications of both the T cell and myeloid compartments. Given evidence of PVR expression on human GBM cells, TIGIT presents as a promising immune therapeutic target in the management of these patients.

KW - CD155

KW - checkpoint inhibitor

KW - dendritic cell

KW - GBM

KW - glioma

KW - immunotherapy

KW - PD-1

KW - PVR

KW - TIGIT

UR - http://www.scopus.com/inward/record.url?scp=85047438297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047438297&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1466769

DO - 10.1080/2162402X.2018.1466769

M3 - Article

C2 - 30221069

AN - SCOPUS:85047438297

VL - 7

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 8

M1 - e1466769

ER -